Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Clover Health Investments Corp (NASDAQ: CLOV) was $3.87 for the day, up 1.57% from the previous closing price of $3.81. In other words, the price has increased by $1.57 from its previous closing price. On the day, 4.32 million shares were traded. CLOV stock price reached its highest trading level at $3.91 during the session, while it also had its lowest trading level at $3.775.
Ratios:
Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 07 ’25 when Edwards Carladenise Armbrister sold 200,000 shares for $3.61 per share. The transaction valued at 722,000 led to the insider holds 273,227 shares of the business.
Priest Brady Patrick sold 75,000 shares of CLOV for $276,000 on Mar 06 ’25. The CEO of Home Care now owns 2,418,151 shares after completing the transaction at $3.68 per share. On Mar 06 ’25, another insider, Soares Karen, who serves as the General Counsel & Secretary of the company, sold 52,500 shares for $3.80 each. As a result, the insider received 199,500 and left with 1,299,663 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1946555648 and an Enterprise Value of 1755654016. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.44 while its Price-to-Book (P/B) ratio in mrq is 5.50. Its current Enterprise Value per Revenue stands at 1.281 whereas that against EBITDA is -39.367.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.00, which has changed by 3.8802018 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -5.91%, while the 200-Day Moving Average is calculated to be 24.87%.
Shares Statistics:
CLOV traded an average of 6.15M shares per day over the past three months and 5021170 shares per day over the past ten days. A total of 395.74M shares are outstanding, with a floating share count of 382.86M. Insiders hold about 25.06% of the company’s shares, while institutions hold 18.20% stake in the company. Shares short for CLOV as of 1740700800 were 11895643 with a Short Ratio of 1.93, compared to 1738281600 on 15081636. Therefore, it implies a Short% of Shares Outstanding of 11895643 and a Short% of Float of 2.8800000999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between -$0.2 and -$0.2 for the fiscal current year, implying an average EPS of -$0.2. EPS for the following year is -$0.12, with 1.0 analysts recommending between -$0.12 and -$0.12.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $476.9M to a low estimate of $460.57M. As of the current estimate, Clover Health Investments Corp’s year-ago sales were $346.92MFor the next quarter, 4 analysts are estimating revenue of $474.88M. There is a high estimate of $491.5M for the next quarter, whereas the lowest estimate is $464.85M.
A total of 4 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.83B, resulting in an average revenue estimate of $1.86B. In the same quarter a year ago, actual revenue was $1.37BBased on 4 analysts’ estimates, the company’s revenue will be $2.2B in the next fiscal year. The high estimate is $2.29B and the low estimate is $2.02B.
